GlycoMimetics (GLYC) Scheduled to Post Earnings on Thursday

GlycoMimetics (NASDAQ:GLYC) is set to announce its earnings results before the market opens on Thursday, August 1st. Analysts expect the company to announce earnings of ($0.36) per share for the quarter.

GlycoMimetics (NASDAQ:GLYC) last announced its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.33) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.01. On average, analysts expect GlycoMimetics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

GLYC stock traded down $0.06 during midday trading on Wednesday, reaching $9.13. 1,654 shares of the company’s stock traded hands, compared to its average volume of 613,785. The firm has a market capitalization of $396.40 million, a P/E ratio of -7.79 and a beta of 2.47. The firm has a fifty day simple moving average of $11.25. The company has a debt-to-equity ratio of 0.02, a quick ratio of 23.88 and a current ratio of 23.88. GlycoMimetics has a 52 week low of $8.29 and a 52 week high of $17.07.

A number of analysts have commented on GLYC shares. Cowen set a $150.00 price target on shares of Tesla and gave the company a “sell” rating in a research note on Friday, May 3rd. Piper Jaffray Companies set a $80.00 price objective on shares of Canopy Growth and gave the stock a “buy” rating in a report on Friday, April 12th. HC Wainwright set a $5.00 price objective on shares of SuperCom and gave the stock a “buy” rating in a report on Friday, April 12th. BidaskClub raised shares of Xilinx from a “hold” rating to a “buy” rating in a report on Wednesday, July 24th. Finally, Zacks Investment Research downgraded shares of GENEL ENERGY PL/ADR from a “hold” rating to a “sell” rating in a report on Thursday, July 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. GlycoMimetics currently has an average rating of “Buy” and an average price target of $23.00.

About GlycoMimetics

GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML.

Read More: Marijuana Stocks

Earnings History for GlycoMimetics (NASDAQ:GLYC)

Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.